
|Articles|July 22, 2022
Daily Medication Pearl: Privigen Immune Globulin Intravenous (Human)
Author(s)Saro Arakelians, PharmD
Privigen is indicated for the treatment of primary humoral immunodeficiency, chronic immune thrombocytopenic purpura in patients 15 years of age and older, chronic inflammatory demyelinating polyneuropathy in adults.
Advertisement
Medication Pearl of the Day: Privigen Immune Globulin Intravenous (Human)
Indication: Privigen is an immune globulin intravenous (human), 10% liquid indicated for the treatment of primary humoral immunodeficiency, chronic immune thrombocytopenic purpura in patients 15 years of age and older, chronic inflammatory demyelinating polyneuropathy in adults.
Insight:
- Dosing: Dosing may vary from 0.5 mg/kg/min to 8 mg/kg/min
- Dosage forms: Privigen is a liquid solution containing 10% IgG (0.1 g/mL).
- Adverse events: The most common adverse reactions, observed in >5% of study subjects, were headache, fatigue, nausea, chills, vomiting, back pain, pain, elevated body temperature, abdominal pain, diarrhea, cough, stomach discomfort, chest pain, joint swelling/effusion, influenza-like illness, pharyngolaryngeal pain, urticaria, and dizziness. Serious adverse reactions were hypersensitivity, chills, fatigue, dizziness, and increased body temperature.
- Mechanism of action: Privigen supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against a wide variety of bacterial and viral agents. The mechanism of action has not been fully elucidated but may include immunomodulatory effects.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Daratumumab and Hyaluronidase-fihj With Quadruplet Regimen for Newly Diagnosed Multiple Myeloma
2
Study Finds No Evidence That Hormone Therapy Use Affects Dementia Risk in Postmenopausal Women
3
FDA Expanded Approval of Imiglucerase Expands Treatment Options for Type 3 Gaucher Disease
4
New AHA Scientific Statement Notes Socioeconomic, Structural Barriers to Addressing Obesity
5


















